Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Works matching AU Wu, Chang-peng
Results: 7
1
2
Clinical Applications of and Challenges in Single-Cell Analysis of Circulating Tumor Cells.
- Published in:
- DNA & Cell Biology, 2018, v. 37, n. 2, p. 78, doi. 10.1089/dna.2017.3981
- By:
- Publication type:
- Article
3
Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
4
Correction to: Synergism between the phosphatidylinositol 3-kinase p110β isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
5
Synergism between the phosphatidylinositol 3-kinase p110β isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation.
- Published in:
- Cancer Cell International, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12935-020-01728-4
- By:
- Publication type:
- Article
6
Synergism between the phosphatidylinositol 3-kinase p110β isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation.
- Published in:
- Cancer Cell International, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12935-020-01728-4
- By:
- Publication type:
- Article
7
Synergism between the phosphatidylinositol 3-kinase p110β isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation.
- Published in:
- Cancer Cell International, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12935-020-01728-4
- By:
- Publication type:
- Article